InflaRx NV

IFRX · NASDAQ

$1.54+$0.09 (+6.21%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.45

Latest news

Press releaseOct 1, 7:30 AM ETGlobe Newswire
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
Press releaseAug 6, 7:30 AM ETGlobe Newswire
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
Press releaseJun 30, 7:30 AM ETGlobe Newswire
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
NewsMay 8, 5:06 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
NewsMay 6, 1:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
Press releaseMay 6, 8:25 AM ETGlobe Newswire
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
Press releaseMay 4, 7:30 AM ETGlobe Newswire
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
Press releaseMay 1, 7:30 AM ETGlobe Newswire
InflaRx to Report First Quarter 2026 Results on May 7, 2026
NewsApr 28, 1:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
Press releaseApr 9, 7:30 AM ETGlobe Newswire
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
Press releaseMar 19, 7:30 AM ETGlobe Newswire
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
NewsMar 19, 7:11 AM ET
Earnings Scheduled For March 19, 2026
NewsMar 18, 5:05 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseJan 8, 8:00 AM ETGlobe Newswire
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation
Press releaseJan 8, 8:00 AM ETGlobe Newswire
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation
NewsDec 5, 7:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsNov 18, 4:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
NewsNov 18, 7:06 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsNov 10, 12:07 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsNov 10, 7:06 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsOct 24, 12:47 PM ETVandana Singh
Biogen's Immunology Pipeline Has Long-Term Potential: Analyst
NewsSep 8, 5:59 AM ETVishaal Sanjay
Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge
NewsAug 28, 1:06 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsMay 28, 12:19 PM ETAvi Kapoor
Crude Oil Gains 2%; Macy's Lowers Earnings Forecast
NewsMay 28, 9:56 AM ETAvi Kapoor
US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings
NewsMay 8, 10:42 AM ETAvi Kapoor
This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday
NewsMay 6, 5:01 PM ET
Preview: InflaRx's Earnings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos

12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases

InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes

InflaRx to Report First Quarter 2026 Results on May 7, 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor

InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

Earnings Scheduled For March 19, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

Biogen's Immunology Pipeline Has Long-Term Potential: Analyst

Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge

12 Health Care Stocks Moving In Thursday's Intraday Session

Crude Oil Gains 2%; Macy's Lowers Earnings Forecast

US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings

This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

Preview: InflaRx's Earnings